Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector, has entered into a supply and production licensing agreement with a leading pharmaceutical company based in Bahrain. This partnership focuses on a range of vaccines, including the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, and a quadruple vaccine combining cell-free pertussis with type B influenza and Hemophilus.
The two companies will collaborate on obtaining regulatory approvals, local raw liquid packaging, and navigating government tender processes for these vaccines across Gulf Cooperation Council (GCC) countries, which include Bahrain, Saudi Arabia, United Arab Emirates, Kuwait, Qatar, and Oman.
These Gulf nations, investing over USD 100 billion in the healthcare sector, represent a lucrative market for vaccine distribution, with the mentioned vaccines already incorporated into local vaccination programs.- Flcube.com
